Subscribe
shutterstock_1827455255_henadzi_kllent
HENADZI KlLENT / Shutterstock.com
25 October 2022Big PharmaStaff Writer

Japanese firm acquires US drugmaker after increasing offer

The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit affirms Latuda decision in Sumitomo clash
19 April 2018   The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.
Americas
Par Pharmaceutical in pre-emptive strike to protect Latuda generic
5 January 2017   Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Federal Circuit affirms Latuda decision in Sumitomo clash
19 April 2018   The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.
Americas
Par Pharmaceutical in pre-emptive strike to protect Latuda generic
5 January 2017   Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.

More on this story

Americas
Federal Circuit affirms Latuda decision in Sumitomo clash
19 April 2018   The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.
Americas
Par Pharmaceutical in pre-emptive strike to protect Latuda generic
5 January 2017   Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages